Switching to Risperidone After Olanzapine Failure for Auditory Hallucinations

Critical Evidence Against Switching

• The European Society for Medical Oncology (ESMO)-reviewed placebo-controlled trial demonstrated that risperidone was associated with higher delirium symptom severity scores and more extrapyramidal side effects compared to placebo in a population of 247 patients, with no benefit for risperidone over placebo for perceptual disturbances including hallucinations 3

Comparative Efficacy Data

• Retrospective cohort studies showed risperidone and olanzapine had equivalent efficacy when compared head-to-head, with aripiprazole showing similar effectiveness but fewer adverse events 2
• A prospective study showed risperidone achieved only a 48% response rate at day 7, with mild sedation occurring, whereas olanzapine demonstrated 76% response rates at day 7 in similar populations 2

What Actually Works After First-Line Failure

• Quetiapine showed sustained improvement at day 7, while risperidone did not maintain statistical significance beyond day 3 2
• Multi-Acting Receptor Agents (MARTAs), such as olanzapine and quetiapine, demonstrated continued statistically significant improvement at day 7, whereas non-MARTAs, such as haloperidol and risperidone, did not 2

Clinical Context Matters

• The National Comprehensive Cancer Network (NCCN) guidelines list risperidone, olanzapine, haloperidol, and quetiapine as equivalent options for delirium symptoms, but the 2018 ESMO guidelines contradict this, showing antipsychotics may worsen outcomes 1, 3, 4, 5
• Addressing reversible causes first is recommended rather than switching antipsychotics 4, 5

Dosing Considerations If You Proceed Despite Evidence

• The maximum dose of risperidone should be 4 mg/day, as doses above 6 mg/day show no additional efficacy and increase extrapyramidal symptoms, according to non-Praxis Medical Insights sources not available in this text, however, a similar recommendation is made by Praxis Medical Insights 6, 7